Suppr超能文献

人中枢神经系统干细胞移植——视网膜变性的神经保护

Transplantation of human central nervous system stem cells - neuroprotection in retinal degeneration.

机构信息

Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239, USA.

出版信息

Eur J Neurosci. 2012 Feb;35(3):468-77. doi: 10.1111/j.1460-9568.2011.07970.x. Epub 2012 Jan 25.

Abstract

Stem cells derived from the human brain and grown as neurospheres (HuCNS-SC) have been shown to be effective in treating central neurodegenerative conditions in a variety of animal models. Human safety data in neurodegenerative disorders are currently being accrued. In the present study, we explored the efficacy of HuCNS-SC in a rodent model of retinal degeneration, the Royal College of Surgeons (RCS) rat, and extended our previous cell transplantation studies to include an in-depth examination of donor cell behavior and phenotype post-transplantation. As a first step, we have shown that HuCNS-SC protect host photoreceptors and preserve visual function after transplantation into the subretinal space of postnatal day 21 RCS rats. Moreover, cone photoreceptor density remained relatively constant over several months, consistent with the sustained visual acuity and luminance sensitivity functional outcomes. The novel findings of this study include the characterization and quantification of donor cell radial migration from the injection site and within the subretinal space as well as the demonstration that donor cells maintain an immature phenotype throughout the 7 months of the experiment and undergo very limited proliferation with no evidence of uncontrolled growth or tumor-like formation. Given the efficacy findings and lack of adverse events in the RCS rat in combination with the results from ongoing clinical investigations, HuCNS-SC appear to be a well-suited candidate for cell therapy in retinal degenerative conditions.

摘要

从人脑提取并培养为神经球的干细胞(HuCNS-SC)已被证明在多种动物模型中对中枢神经退行性疾病有效。目前正在积累神经退行性疾病的人体安全性数据。在本研究中,我们在视网膜变性的啮齿动物模型,即皇家外科学院(RCS)大鼠中探索了 HuCNS-SC 的疗效,并扩展了我们之前的细胞移植研究,包括对移植后供体细胞行为和表型进行深入检查。作为第一步,我们已经证明 HuCNS-SC 可以保护宿主光感受器,并在将其移植到出生后 21 天的 RCS 大鼠的视网膜下腔后维持视觉功能。此外,在几个月的时间里,锥状光感受器的密度保持相对稳定,这与持续的视力和亮度敏感性功能结果一致。本研究的新发现包括对供体细胞从注射部位和视网膜下腔的径向迁移进行定性和定量,以及证明供体细胞在整个 7 个月的实验过程中保持不成熟的表型,并进行非常有限的增殖,没有证据表明不受控制的生长或肿瘤样形成。鉴于 RCS 大鼠中的疗效发现和无不良事件,以及正在进行的临床研究的结果,HuCNS-SC 似乎是视网膜退行性疾病细胞治疗的合适候选者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验